XML 72 R54.htm IDEA: XBRL DOCUMENT v3.22.1
Held for Sale - Narrative (Details)
€ in Millions, £ in Millions, $ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2022
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Apr. 30, 2022
GBP (£)
Jan. 31, 2022
USD ($)
Jan. 31, 2022
EUR (€)
Jul. 05, 2021
USD ($)
Jul. 05, 2021
EUR (€)
Nov. 01, 2020
USD ($)
Discontinued Operations Disclosures                      
Assets held for sale   $ 4,516 $ 4,516 $ 12              
Liabilities held for sale   4,741 4,741 9              
Charge for remeasurement to fair value     1,509 0 $ 0            
German Pharmaceutical Wholesale Joint Venture                      
Discontinued Operations Disclosures                      
Carrying value of investment in joint venture       0              
Held-for-sale                      
Discontinued Operations Disclosures                      
Assets held for sale   4,500 4,500 12              
Liabilities held for sale   4,700 4,700 9              
International                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value       58 275            
German Wholesale Business                      
Discontinued Operations Disclosures                      
Proceeds from collection of notes receivable       291              
Consideration receivable                     $ 41
German Wholesale Business | International | Held-for-sale | Walgreens Boots Alliance Joint Venture | Operating Segments                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value       58 275            
Ownership interest in Joint Venture (percent)                     30.00%
European Businesses (Disposal Group) | Held-for-sale                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value     1,600                
Austrian Business Operations | Held-for-sale                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value     32                
Proceeds from collection of notes receivable   63                  
Net Assets   $ 272 272                
Consideration agreed upon for sale of business             $ 276 € 244      
Held-for-sale | German Pharmaceutical Wholesale Joint Venture                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value       $ 58 $ 275            
E.U. Businesses (Disposal Group) | Held-for-sale                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value     438                
Gross purchase price                 $ 1,400 € 1,200  
Accumulated other comprehensive loss in charge for remeasurement to fair value     151                
E.U. Businesses (Disposal Group) | International | Held-for-sale | Operating Segments                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value     383                
U.K. Businesses (Disposal Group) | Held-for-sale                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value     1,200                
Accumulated other comprehensive loss in charge for remeasurement to fair value     734                
U.K. Businesses (Disposal Group) | Held-for-sale | Subsequent Event                      
Discontinued Operations Disclosures                      
Gross purchase price $ 144         £ 110          
Proceeds from collection of notes receivable $ 118                    
U.K. Businesses (Disposal Group) | International | Held-for-sale | Operating Segments                      
Discontinued Operations Disclosures                      
Charge for remeasurement to fair value     $ 1,100